Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care

David Price,1,2* Henry Chrystyn,3 Alan Kaplan,1 John Haughney,1 Miguel Román-Rodríguez,5 Annie Burden,2 Alison Chisholm,2 Elizabeth V. Hillyer,2 Julie von Ziegenweidt,2 Muzammil Ali,2 Thys van der Molen6

1Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
2Research in Real Life Ltd, Cambridge, UK
3School of Applied Sciences, University of Huddersfield, West Yorkshire, UK
4Family Physician Airways Group of Canada, Richmond Hill, ON, Canada
5Son Pisa Primary Health Care Centre, Balearic Health Service, Palma de Mallorca, Spain
6Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Purpose: Correct use of inhaler devices is fundamental to effective asthma management but represents an important challenge for patients. The correct inhalation manoeuvre differs markedly for different inhaler types. The objective of this study was to compare outcomes for patients prescribed the same inhaler device versus mixed device types for asthma controller and reliever therapy. Methods: This retrospective observational study identified patients with asthma (ages 4-80 years) in a large primary care database who were prescribed an inhaled corticosteroid (ICS) for the first time. We compared outcomes for patients prescribed the same breath-actuated inhaler (BAI) for ICS controller and salbutamol reliever versus mixed devices (BAI for controller and pressurised metered-dose inhaler [pMDI] for reliever). The 2-year study included 1 baseline year before the ICS prescription (to identify and correct for confounding factors) and 1 outcome year. Endpoints were asthma control (defined as no hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and severe exacerbations (hospitalisation or oral corticosteroids for asthma). Results: Patients prescribed the same device (n=3,428) were significantly more likely to achieve asthma control (adjusted odds ratio, 1.15; 95% confidence interval [CI], 1.02-1.28) and recorded significantly lower severe exacerbation rates (adjusted rate ratio, 0.79; 95% CI, 0.68-0.93) than those prescribed mixed devices (n=5,452). Conclusions: These findings suggest that, when possible, the same device should be prescribed for both ICS and reliever therapy when patients are initiating ICS.

Key Words: Asthma; breath-actuated inhaler; inhaled corticosteroids; inhaler device; pressurised metered-dose inhaler; short-acting β2-agonist

INTRODUCTION

Correct use of inhaler devices is fundamental to effective asthma management but represents an important challenge for patients. Both bronchodilator reliever therapy (short-acting β2-agonist [SABA]) and most asthma controller (preventer) therapies, including inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA), are delivered by inhalation. Numerous clinical investigations report errors in inhaler device handling by patients, even by those classified as experienced in using their asthma inhalers.1–4 Inhaler mishandling, in turn, has been linked to reduced asthma control, with increased risk of exacerbations and unscheduled care for asthma.1,5

The correct inhalation manoeuvre differs for different inhaler types.6–9 Pressurised metered-dose inhalers (pMDIs) are actuated by pressing down on the canister to release a dose in coordination with the start of inhalation. Breath-actuated metered-dose inhalers (BAIs) and dry powder inhalers (DPIs) are actuated by the patient’s inhalation but vary in requirements for inhalation speed and character, which should be slow and deep with a BAI but sharp and rapid with a DPI.

Because of these differences, several authors have recommended that patients should always be prescribed the same device...
type for each asthma medication.\textsuperscript{7-11} It would seem logical that confusion could result from using different inhaler device types for asthma controller and reliever therapy, especially for patients just beginning inhaler therapy who lack long-term training and practice with different devices. However, there is actually little definitive research into this topic. In their observational study of 321 adult outpatients with asthma, van der Palen and co-authors\textsuperscript{12} used a check-list to assess inhaler technique and found no errors among 71\% of patients using only one inhaler as compared with 61\% of patients using two or more different inhalers. They concluded that the same type of inhaler should be prescribed and that if this is not possible then a combination of two different DPIs is preferable to a DPI-pMDI combination. They did not examine asthma control in relation to inhaler technique, nor, to our knowledge, have other studies investigated this.

Retrospective database studies can be used to examine the comparative effectiveness of interventions for real-world patients under real-world conditions of clinical care. Our objective in this study was to determine whether outcomes differed for primary care patients in the UK who were prescribed the same BAI device for asthma controller and reliever therapy as compared with mixed devices (BAI plus pMDI). We focused on BAs, as these are often used for controller therapy but not always in conjunction with a breath-actuated reliever because the latter is more expensive than a SABA pMDI.

MATERIALS AND METHODS

Data source and patients

This retrospective observational study drew on anonymised patient data contained in the General Practice Research Database (GPRD), a large primary care database containing prescription and other medical record information for patients at over 500 participating clinical practices throughout the UK.\textsuperscript{13} The GPRD is a well-regarded and validated data source for pharmacoepidemiologic research, including respiratory and prescribing research.\textsuperscript{14-16}

This study analysed data for patients with asthma aged 4-80 years who received beclometasone dipropionate by Easi-Breathe BAI as their first ICS prescription, together with a prescrip tion for reliever therapy (salbutamol) by either Easi-Breathe BAI or pMDI. These particular combinations allowed for comparability of formulation and drug, as salbutamol pMDI and BAl contain a pressurised aerosol with similar characteristics and the only difference being between the breath actuation amendments. Evidence of asthma in the database was defined as a coded diagnosis of asthma, two or more prescriptions for asthma at different timepoints during the baseline year, or two or more prescriptions for asthma during the outcome year that included at least one ICS prescription. Patients over 60 years old who smoked were excluded from the study to minimise inclusion of patients with concomitant chronic obstructive pulmonary disease (COPD). In addition to COPD, other exclusion criteria were any other chronic respiratory disease, a prescription for asthma controller therapy (ICS or LABA) during the baseline year, or a LABA prescription at the index date.

The study period spanned 16 and a half years from January 1991 through June 2007, a period when all devices of interest were available. As SABA is not always prescribed on the same day as ICS, we prioritised as follows to identify each patient’s salbutamol device for the study: (1) the salbutamol prescribed at the index date; (2) the salbutamol prescribed at the closest date before the index date; or (3) the first salbutamol prescribed after the index date if there were no recorded prescriptions before the index date. Eligible patients were required to have 2 continuous years of data in the GPRD, including a baseline year for confounder definition and an outcome year, and to be enrolled at practices with data assessed as up-to-standard by the GPRD during the years in question.

Effectiveness endpoints

The co-primary endpoints, defined in Table 1, were designed to capture evidence of asthma control and rate of severe exacerbations during the outcome year, in accordance with recommendations of the joint European Respiratory Society/American Thoracic Society Task Force on outcome measures for asthma trials.\textsuperscript{19}

Secondary endpoints included two composite measures of treatment success and the rate of respiratory-related hospitalisations (Table 1).

Statistical analyses

Summary statistics were used to assess all baseline and outcome variables. Continuous variables were compared using the t test for normally distributed data and the Mann-Whitney test (Wilcoxon rank sum test) for skewed data; categorical variables were compared using the \( \chi^2 \) test. Differences between treatment cohorts with \( P<0.10 \) were examined for collinearity as well as clinical importance to select those used as potential confounders in the regression modelling of outcomes.

Multivariate analyses were used to identify baseline variables predictive \( (P<0.05) \) of outcomes; these were considered as potential additional confounders when modelling outcome variables. Spearman correlation coefficients were calculated between all potential confounders to determine strengths of linear relationships between variables; the correlation coefficients were considered, in conjunction with clinical interpretation, to identify possible collinearity issues. All outcomes were adjusted for appropriate non-collinear baseline confounders.

The adjusted odds of achieving asthma control was compared between treatment cohorts using a binary logistic regression model. Asthma control status was used as the dependent variable with treatment and potential confounding factors as explanatory variables. The same model was used to assess other
Table 1. Study endpoint definitions

**Asthma control,** includes all of the following:
1. no recorded hospital attendance for asthma, including admission, A&E attendance, out-of-hours attendance, or OPD attendance;
2. no prescription for oral corticosteroids; and
3. no general practice consultation, hospital admission, or A&E attendance for LRTI requiring antibiotics

**Severe exacerbation,** defined as any of the following:
1. unscheduled hospital admission or A&E attendance for asthma, or
2. a prescription for oral corticosteroids

**Treatment success-1,** includes all of the following:
1. no severe exacerbations;
2. no consultations, hospital admissions, or A&E attendance for LRTI requiring antibiotics; and
3. no change in therapeutic regimen, where a change could be any of the following:
   a. ≥50% increase in ICS dose,
   b. change in ICS,
   c. change in ICS inhaler device, or
   d. use of additional therapy for asthma, including theophylline or LTRA

**Treatment success-2,** includes all of the following:
1. no severe exacerbations;
2. no consultations, hospital admissions, or A&E attendance for LRTI requiring antibiotics; and
3. no change in therapeutic regimen, where a change could be any of the following:
   a. ≥50% increase in ICS dose, or
   b. use of additional therapy for asthma, including theophylline or LTRA

**Respiratory-related hospitalisations,** including respiratory-related referrals

*Co-primary endpoints; †Treatment success-2 differs from treatment success-1 in excluding the changes in therapeutic regimen that could be attributed to cost-saving measures.

A&E, Accident & Emergency; ICS, inhaled corticosteroid; LRTI, lower respiratory tract infection; LTRA, leukotriene receptor antagonist; OPD, Outpatient Department.

binary outcomes. A Poisson regression model was used to compare the total number of severe exacerbations in the outcome period between treatment cohorts and to obtain estimates of exacerbation rates. The model was adjusted for over-dispersion using robust standard errors, and adjustments were made for potential baseline confounders. This model was used also to analyse respiratory-related hospitalisation rates.

Study endpoints and the main analyses were established according to standard operating procedures of the study group.28 We also performed a post hoc sensitivity analysis to explore differences in odds of asthma control and severe exacerbation rates after excluding children (ages 4-11) as well as patients receiving the highest doses of ICS at the index date.

Adjusted odds ratios and rate ratios were calculated together with 95% confidence intervals. Statistical significance was defined as \( P < 0.05 \) and trends as \( 0.05 \leq P < 0.10 \). All analyses were carried out using SPSS/PASW versions 17 and 18 (SPSS Statistics, IBM, Somers, NY, USA), SAS version 9.2 (SAS Institute, Marlow, Buckinghamshire, UK), and Excel 2007 (Microsoft, Bellevue, WA, USA).

**RESULTS**

**Patients**

We identified 8,880 patients who met study selection criteria: 3,428 in the same device cohort (who received Easi-Breathe inhalers for both beclometasone and salbutamol) and 5,452 in the mixed devices cohort (who received beclometasone by Easi-Breathe and salbutamol by pMDI). Fig. 1 depicts the patient selection process, and Table 2 summarises patient characteristics at the index date. Approximately one quarter (2,107 or 23.7%) of patients were children aged 4-11 years. Of these, 45% were girls, whereas in the full cohort, 59% were female. The mean year of the index date was 1999 in both cohorts.

There were several statistically significant differences in demographic characteristics between the cohorts at baseline (Table 2), with proportionately more female patients and more
Table 2. Baseline demographic and clinical characteristics of patients with asthma receiving their first ICS prescription via BAI together with salbutamol via BAI (same device) or with salbutamol via pMDI (mixed devices)

| Characteristic                          | Same device (n=3,428) | Mixed devices (n=5,452) | P-value* |
|----------------------------------------|-----------------------|-------------------------|----------|
| Female sex, n (%)                      | 2,109 (61.5)          | 3,101 (56.9)            | <0.001   |
| Age at index date, median (IQR)        | 31 (13-49)            | 28 (11-45)              | <0.001   |
| 4-11 yr, n (%)                         | 675 (19.7)            | 1,432 (26.3)            | -        |
| 12-80 yr, n (%)                        | 2,753 (80.3)          | 4,020 (73.7)            | -        |
| Weight (kg), mean (SD)                 | 69.9 (22.3)           | 67.6 (24.1)             | 0.015    |
| Height (m), mean (SD)                  | 1.62 (0.15)           | 1.60 (0.20)             | 0.315    |
| BMIV (kg/m²), mean (SD)†              | 26.0 (6.6)            | 25.3 (6.6)              | <0.001   |
| BMIV (kg/m²) > 30, n (%)†              | 566 (22.4)            | 763 (19.6)              | -        |
| Socioeconomic status, median (IQR)§    | 17.6 (8.1-32.7)       | 16.4 (8.7-32.7)         | 0.016    |

¶ Charlson comorbidity index, n (%): 0 3,059 (89.2) 4,975 (91.3) 0.002 1 369 (10.8) 477 (8.7) Recorded smoking status, n/total n (%): 1,357/3,428 (39.6) 2,091/5,452 (38.4) Current smokers 604/1,357 (44.5) 883/2,091 (42.2) <0.001 Ex-smokers 261/1,357 (19.2) 546/2,091 (26.1) Non-smokers 492/1,357 (36.3) 662/2,091 (31.7) Recorded comorbidity, n (%): Rhinitis 639 (18.6) 980 (18.0) 0.429 Cardiac disease 566 (16.2) 695 (12.7) <0.001 GERD‡ 445 (13.0) 655 (12.0) 0.178 1+ prescription in 12 mo, n (%): NSAID 623 (18.2) 888 (16.3) 0.021 Beta blocker 172 (5.0) 212 (3.9) 0.011 Paracetamol 644 (18.8) 1,142 (20.9) 0.013 *Categorical values were compared with the χ² test and continuous variables with the Mann-Whitney test; †Weight and height were recorded closest to the index date; for children <12, weight and height were included only if within 2 years of index date. Not all patients had recorded weight and height data. For weight, n = 2,564 (74.8%) and 3,984 (73.1%); height n = 2,696 (78.6%) and 4,225 (77.5%); BMI n = 2,483 (72.4%) and 3898 (71.3%) for same and mixed devices cohort, respectively; §Socioeconomic status was that assigned, in quintiles, by the General Practice Research Database to each practice using the Index of Multiple Deprivation as a proxy measure. The Charlson comorbidity index is a weighted index that accounts for number and severity of comorbidities, each assigned a score depending on the associated risk of dying; ‡Patients with cardiac disease and GERD included those with a recorded diagnosis or recorded prescription for same. BAI, breath-actuated inhaler; BMIV, body mass index; GERD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroid; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug; pMDI, pressurised metered-dose inhaler; SD, standard deviation.

Table 3. Asthma-related parameters and medical resource use during the baseline year before the first ICS prescription for patients prescribed ICS and salbutamol via same or mixed inhaler device type

| Characteristic                          | Same device (n=3,428) | Mixed devices (n=5,452) | P-value* |
|----------------------------------------|-----------------------|-------------------------|----------|
| Recorded asthma diagnosis, n (%)       | 3,147 (91.8)          | 5,045 (92.5)            | 0.209    |
| Prior SABA inhaler device‡             | None 2,237 (65.3)     | 3,516 (64.5)            | -        |
|                                      | pMDI 270 (7.9)        | 1,519 (27.9)            | -        |
|                                      | BAI 848 (24.7)        | 351 (6.4)               | -        |
|                                      | DPI 71 (2.1)          | 63 (1.2)                | -        |
|                                      | Various (BAI + MDI or DPI + pMDI) 2 (0.0) 3 (0.0) - |
| Mean daily SABA use, no. (%)§         | none 1,525 (44.5)     | 2,279 (41.8)            | <0.001   |
|                                      | ≤ 3.5 doses/wk 1,118 (32.6) 1,647 (30.2) - |
|                                      | >0.5-1 dose/d 566 (16.5) 962 (17.6) - |
|                                      | > 1 dose/d 219 (6.4) 564 (10.3) - |
| Oral corticosteroid courses, n (%)     | 0 2,857 (83.3)        | 4,549 (83.4)            | 0.441    |
|                                      | 1 461 (13.4)          | 700 (12.8)              | -        |
|                                      | 2 81 (2.4)            | 157 (2.9)               | -        |
|                                      | ≥ 3 29 (0.8)          | 46 (0.8)                | -        |
| Total severe exacerbations, n (%)§     | 0 2,855 (83.3)        | 4,534 (83.2)            | 0.518    |
|                                      | 1 461 (13.4)          | 712 (13.1)              | -        |
|                                      | 2 83 (2.4)            | 160 (2.9)               | -        |
|                                      | ≥ 3 29 (0.8)          | 46 (0.8)                | -        |
| ICS dose prescribed at index date, n (%) | 1-200 μg/d 815 (23.8) 1,507 (27.6) <0.001 |
|                                      | 201-400 μg/d 1,985 (57.9) 3,430 (62.9) - |
|                                      | 401-800 μg/d 250 (7.3) 331 (6.1) - |
|                                      | >800 μg/d 378 (11.0) 184 (3.4) - |
| Asthma consultations, n (%)           | 0 1,457 (42.5)        | 2,399 (44.0)            | <0.001   |
|                                      | 1 1,352 (39.4)        | 2,054 (37.7)            | -        |
|                                      | 2 464 (13.5)          | 651 (11.9)              | -        |
|                                      | ≥3 155 (4.5)          | 348 (6.4)               | -        |
| Total consultations, n (%)            | 0-2 822 (24.0)        | 1,221 (22.4)            | 0.065    |
|                                      | 3-4 794 (23.2)        | 1,193 (21.9)            | -        |
|                                      | 5-6 620 (18.1)        | 997 (18.3)              | -        |
|                                      | 7-9 581 (16.9)        | 944 (17.3)              | -        |
|                                      | ≥10 611 (17.8)        | 1,097 (20.1)            | -        |
| Asthma prescriptions, n (%)           | 0 981 (28.6)          | 1,458 (26.7)            | <0.001   |
|                                      | 1 1,063 (31.0)        | 1,549 (28.4)            | -        |
|                                      | 2 882 (25.7)          | 1,463 (26.8)            | -        |
|                                      | ≥5 502 (14.6)         | 982 (18.0)              | -        |

(Continued to the next page)
Table 3. (Continued from the previous page) Asthma-related parameters and medical resource use during the baseline year before the first ICS prescription for patients prescribed ICS and salbutamol via same or mixed inhaler device type

| Characteristic | Same device (n=3,428) | Mixed devices (n=5,452) | Pvalue* |
|----------------|------------------------|------------------------|---------|
| Courses of antibiotics for LRTI, n (%) | | | |
| 0 | 2,744 (80.0) | 4,312 (79.1) | 0.528 |
| 1 | 497 (14.5) | 836 (15.3) | |
| ≥2 | 187 (5.5) | 304 (5.6) | |
| Asthma control status, n (%)† | | | |
| none | 2,346 (66.4) | 3,689 (67.7) | 0.465 |
| 1 | 170 (4.9) | 215 (4.0) | |
| 2 | 406 (11.9) | 572 (10.5) | |
| ≥3 | 304 (8.8) | 479 (8.7) | |

*Categorical values were compared with the χ² test and continuous variables with the Mann-Whitney test; †The prior SABA device type was included only for the baseline year; thus, because some patients had a pre-baseline SABA prescription, ~55% of patients used SABA during the baseline year but only ~35% of patients had a SABA prescription in the baseline period; ‡The SABA dose is the salbutamol dose equivalent (standard dose in UK is 200 µg). Thus, patients who used >0.5-1 dose/d, 101-200 µg/d, and those who used >1 dose/d, >200 µg/d; §A severe exacerbation was defined as an unaccompanied hospital admission or emergency room attendance for asthma or prescription for oral corticosteroids; exacerbations on the index date were included in the baseline data; ††Asthma control was defined as no hospital attendance for asthma, oral corticosteroid course, or antibiotics for LRTI during the baseline year.

Outcomes

There were several statistically significant differences between cohorts in the unadjusted outcomes, summarised in Table 4. More patients in the same device cohort consumed a mean daily ICS dose of >400 µg/day, and fewer used no SABA, during the outcome year, as compared with patients in the mixed devices cohort. (The daily ICS and salbutamol doses consumed during the outcome year were calculated as the dispensed amount divided by 365. ICS, inhaled corticosteroid; LRTI, lower respiratory tract infection.)

Table 4. Outcomes over 1 year after the first ICS prescription for patients prescribed ICS and salbutamol via same or mixed inhaler device type

| Outcome | Same device (n=3,428) | Mixed devices (n=5,452) | Pvalue* |
|---------|------------------------|------------------------|---------|
| Asthma control, n (%) | 2,767 (80.7) | 4,300 (78.9) | - |
| Treatment success-1, n (%) | 2,168 (63.2) | 3,338 (61.2) | - |
| Treatment success-2, n (%) | 2,388 (69.7) | 3,762 (69.0) | - |
| Severe exacerbations, n (%) | 3,070 (89.6) | 3,872 (82.2) | |
| Mean daily salbutamol dose, n (%) | | | |
| none | 281 (8.2) | 612 (11.2) | 0.001 |
| ≤3.5 doses/wk | 851 (24.8) | 1,308 (24.0) | |
| >0.5-1 dose/d | 1,159 (33.8) | 1,720 (31.5) | |
| >1-2 doses/d | 780 (22.8) | 1,238 (22.7) | |
| >2 doses/d | 357 (10.4) | 573 (10.5) | |
| Mean daily ICS dose, n (%) | | | |
| 1-100 µg/d | 842 (24.6) | 1,696 (31.1) | <0.001 |
| 101-200 µg/d | 1,033 (30.1) | 1,709 (31.3) | |
| 201-400 µg/d | 887 (25.9) | 1,297 (23.8) | |
| >400 µg/d | 666 (19.4) | 750 (13.8) | |

Disaggregated outcomes of the composite endpoints:

| Change in therapy, n (%) | 863 (25.2) | 1,449 (26.6) | 0.143 |
| ≥50% increase in ICS dose, n (%) | 445 (13.0) | 729 (13.4) | 0.597 |
| Change in ICS drug | 0 | 0 | - |
| Change in inhaler device | 299 (8.7) | 565 (10.7) | 0.002 |
| Additional therapy | 119 (3.5) | 135 (2.5) | 0.006 |

*Categorical values were compared with the χ² test and continuous variables with the Mann-Whitney test; †See Table 1 for definitions of study endpoints; ‡The standard dose of salbutamol in the UK is 200 µg. Thus, patients who used ≤3.5 doses/wk averaged 1-100 µg/d; those who used >0.5-1 dose/d, 101-200 µg/d, and those who used >1 dose/d, >200 µg/d; ††A severe exacerbation was defined as an unaccompanied hospital admission or emergency room attendance for asthma or prescription for oral corticosteroids; exacerbations on the index date were included in the baseline data; †††Asthma control was defined as no hospital attendance for asthma, oral corticosteroid course, or antibiotics for LRTI during the baseline year.

During the baseline year, the proportions of patients in each cohort who met study criteria for the asthma control measure were similar, as were those who had experienced a severe exacerbation (Table 3). Patients in the mixed devices cohort were more likely to have received paracetamol, a higher SABA dose, and more asthma prescriptions than those in the same device cohort during the baseline year (Tables 2 and 3). At the index date, the median (IQR) prescribed ICS doses were 400 (400-400) µg and 400 (200-400) µg in the same device and mixed devices cohorts, respectively (P<0.001). There were more patients in the same device cohort who received a high ICS dose (>800 µg/day; Table 3). Of the patients with known height and weight who were prescribed doses >800 µg/day, the proportions who were obese (body mass index ≥30 kg/m²) were similar in the two cohorts, namely 82/327 (25.1%) and 37/153 (24.2%).

Current smokers in the same device cohort. The median age was higher in the same device cohort, and patients were heavier with somewhat higher BMI.
Fig. 2. Study endpoint results (adjusted odds ratios and rate ratios) over 1 year after the first ICS prescription for patients prescribed ICS and salbutamol via same device (n=3,428) as compared with mixed inhaler device types (n=5,452). Mixed devices: RR/OR = 1.0.

*Adjusted for age, sex, paracetamol prescriptions, number of GP surgery consultations, number of GP out-of-hours consultations, GERD, gender, and diagnosis, and time between diagnosis and the index date; **Sensitivity analysis excluded patients younger than 12 years and those prescribed >800 µg/day on the index date (same device cohort n=2,392; mixed devices cohort n=3,841). Adjusted for age, sex, number of GP home visits, number of GP out-of-hours consultations, and time between diagnosis and the index date; †Adjusted for age, asthma prescriptions, NSAID prescriptions, number of planned OPD visits, number of asthma consultations, number of GP out-of-hours consultations, number of telephone consultations, and time between diagnosis and the index date; ‡Sensitivity analysis excluded patients younger than 12 years and those prescribed >800 µg/day on the index date. Adjusted for age, acute oral corticosteroids, number of primary care consultations, and time between diagnosis and the index date; ††Adjusted for age, SES, asthma prescriptions, NSAID prescriptions, CCI score, number of primary care consultations, ICS dose at the index date, and time between diagnosis and the index date; †‡Adjusted for age, SES, asthma prescriptions, NSAID prescriptions, number of primary care consultations, number of planned OPD appointments, ICS dose at IPD, and time between diagnosis and the index date; †§Adjusted for age, baseline number of asthma-related hospitalisations, number of planned OPD visits, and number of GP out-of-hours consultations. CCI, Charlson comorbidity index; GP, general practice; GERD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroid; IPD, index prescription date; NSAID, nonsteroidal anti-inflammatory drug; OPD, Outpatient Department; OR, odds ratio; RR, rate ratio; SES, socioeconomic status.

Patients in the same device cohort were significantly more likely to achieve asthma control during the outcome year, and they experienced a significantly lower rate of severe exacerbations, than those in the mixed devices cohort (Fig. 2). Moreover, treatment success-1 was significantly more likely for patients in the same device cohort. There were no differences between cohorts in the adjusted odds for treatment success-2 or in the adjusted rate of respiratory-related hospitalisations (Fig. 2).

Because of recorded differences between cohorts in both prescribed ICS dose at the index date and ICS dose consumed over the outcome year, we examined the percentage of patients who achieved asthma control according to index date ICS dose. The differences between cohorts in asthma control were evident at the lower ICS doses, whilst at the higher ICS doses the percentages of patients achieving control in each cohort were similar (Table 5).

DISCUSSION

The results of this retrospective observational study indicate that over 1 year after a first ICS prescription, patients prescribed the same inhaler device type for both ICS controller and salbutamol reliever therapy were significantly more likely to achieve asthma control than those prescribed mixed devices. Moreover, patients prescribed the same inhaler device type had a significantly lower recorded rate of severe exacerbations requiring a hospital visit or oral corticosteroid course, as well as higher odds of treatment success after incorporating changes in therapeutic regimen. The two treatment cohorts had comparable rates of respiratory-related hospitalisations and odds of treatment success after excluding changes in therapeutic regimen that could be driven by cost savings.

A small proportion of patients in the same device cohort were prescribed a higher ICS dose at the index date than those in the mixed devices cohort, and the median ICS dose consumed during the outcome year was significantly higher in the same device cohort. However, we believe it unlikely that ICS dose influenced outcomes in favour of the same device cohort. Firstly, the sensitivity analysis that excluded patients prescribed high doses of beclometasone (>800 µg/day) and paediatric patients (ages 4-11) supported the main analyses. Secondly, the differences between treatment cohorts in the proportion of patients achieving asthma control were driven by patients receiving the

Table 5. Percentages of patients who achieved asthma control, according to index date ICS dose

| ICS Dose at index date, n (%) | SAME devices | MIXED devices | Pvalue* |
|-----------------------------|-------------|---------------|--------|
| 1-200 µg/d                  | 83%         | 81%           | <0.001 |
| 201-400 µg/d                | 82%         | 79%           |       |
| 401-800 µg/d                | 73%         | 74%           |       |
| ≥801 µg/d                   | 75%         | 75%           |       |

*χ² test
ICS, inhaled corticosteroid.
lower ICS doses (similar proportions of patients achieved asthma control in the higher ICS dose categories).

The problem and prevalence of incorrect inhaler use have been the subject of several reviews over the last decade. Proposed solutions to this problem include educating health-care providers about different inhaler device characteristics; individualising inhaler selection; accommodating patient preferences with regard to their inhaler device; reinforcing inhaler technique at each visit; using tools for training and checking technique; and avoiding a switch in ICS device without an accompanying consultation. The results of this study suggest an additional solution, namely, that, when possible, patients—especially those initiating ICS therapy—should be prescribed the same type of device for their asthma controller and reliever therapy.

We can speculate why patients prescribed the same device type had better outcomes. Specifically, because both ICS drug and device were the same in both cohorts, and the SABA formulations in the two devices are the same, it is reasonable to conclude that the findings likely relate to the impact of salbutamol inhaler device choice. However, it is the ICS that influences asthma control and future risk of asthma exacerbations; SABA does not determine asthma control. Therefore, the outcomes in this study most likely result from the effect on ICS inhaler technique of mixing devices, very possibly because the need to use different breathing patterns with the two devices adversely impacted ICS inhaler technique.

The strengths of this study include the large patient population and the 1-year outcome period, which allowed us to examine less frequent outcomes such as hospitalisations and minimised the influence of seasonal changes in asthma and allergies. The GPRD is an established source for primary care data and draws from a geographically and socioeconomically diverse population; this improves the generalisability, or applicability, of study results to real-world clinical practice. We note that the prescribing patterns recorded in this study were rational, namely, as the ICS dose increased, the percentages of patients meeting the study asthma control measure decreased, suggesting that higher doses were prescribed for patients with more difficult asthma.

While there were some differences between study cohorts at baseline, the two cohorts were comparable in terms of baseline asthma control and severe exacerbations. Moreover, the effectiveness analyses adjusted for differences between cohorts determined to be potential confounders. For example, at baseline the mixed devices cohort was more likely to use more SABA and to have more asthma prescriptions; however, neither of these variables had a significant effect on the asthma control outcome and thus were omitted from the final model. Instead, for the severe exacerbation outcome, the model was adjusted for baseline differences in asthma prescriptions.

The composite asthma control endpoint was designed to capture indicators of asthma control that would be recorded in the GPRD, including unscheduled asthma care and hospitalisations, oral corticosteroid prescriptions, and antibiotic prescriptions for lower respiratory tract infection, as in real-world practice asthma exacerbations can be confused for acute respiratory infections. There were some significant differences between cohorts in the unadjusted results of the disaggregated outcome measures, including more patients in the same devices cohort who took additional therapy (3.5% vs. 2.5%) and more patients in the mixed devices cohort who had a change in inhaler device (8.7% in same devices cohort vs. 10.7%) and overall with a change in therapy (25.2% same devices vs. 26.6% mixed devices cohort); however, these differences were small and unlikely to be clinically significant.

Study findings should be interpreted with an understanding of potential study limitations, common to observational studies. These include the potential for unrecognised confounding factors, including selection bias. Moreover, while the GPRD is recognised to be a high-quality database, there were missing data for some patients, including smoking history, that could influence outcomes. The smoking status was more likely to be recorded for patients with more difficult disease (i.e., those not achieving asthma control), a possible explanation for the high recorded smoking prevalence (43%) among the 40% of patients with recorded smoking history. While there is no assurance that patients actually took the medications as prescribed and dispensed, it is unlikely there would be differences between cohorts in this parameter that could bias the results. In the UK, the pharmacist must dispense as prescribed by the physician, and the GPRD prescribing data are considered a reliable proxy for dispensed medications. Finally, the consistency of the outcomes, including the sensitivity analyses, provide support for the overall findings.

In conclusion, we found that patients prescribed the same BAI device for both controller ICS and reliever salbutamol therapy had better odds of asthma control and lower risk of severe exacerbations over 1 year after their first ICS prescription than those prescribed a BAI for ICS and a pMDI for salbutamol. These findings suggest that, when possible, the same device should be prescribed for both ICS and reliever therapy when patients are initiating ICS. The devices we studied are relatively similar, and it is possible that the adverse effects of mixing other device types, such as DPIs and pMDIs, might be greater. Further research is needed to investigate asthma-related outcomes with other potential inhaler device combinations and whether consistent device prescribing is optimal also for other inhaler device types.

ACKNOWLEDGMENTS

Access to data from the General Practice Research Database was funded by Merck & Co., Inc. (Whitehouse Station, NJ, USA), and the analysis was funded by Teva Pharmaceuticals Limited of Petach Tikwa, Israel. The study sponsor played no role in the
study design; the collection, analysis, and interpretation of data; the writing of the manuscript; or the decision to submit the manuscript for publication. Merck played no role in the study.

REFERENCES

1. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishan-dling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8.

2. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54.

3. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, Canes-sa PA, Neri M, Melani AS; Associazione Italiana Pneumologi Os-pedalieri Educational Group. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med 2006;19:127-36.

4. Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML. Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J 2011;20:292-6.

5. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19:246-51.

6. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J 2009;18:243-9.

7. Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PN; ADMIT Working Group. The ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J 2009;18:76-82.

8. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, Barnes PJ. Importance of inhaler devices in the management of airway disease. Respir Med 2008;102:10-9.

9. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104:1237-45.

10. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device se-lection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-71.

11. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Mof-fat M, Versnel J, Shanahan ER, Hillyer EV, Tunsäter A, Bjerner L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102:1681-93.

12. van der Palen J, Klein Jj, van Hervawarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7.

13. General Practice Research Database. The Medicines and Health-care Products Regulatory Agency [Internet]. London; [cited 2011 Oct 25]. Available from: http://www.gprd.com/.

14. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9.

15. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999;54:413-9.

16. Petersen I, Johnson AM, Islam A, Duckworth G, Livermore DM, Hayward AC. Protective effect of antibiotics against serious complica-tions of common respiratory tract infections: retrospective co-hort study with the UK General Practice Research Database. BMJ 2007;335:982.

17. Thomas M, von Zieglenbein J, Lee AJ, Price D. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol 2009;123:116-21.e10.

18. Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Zieglenbein J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010;126:511-8.e1-10.

19. Reddell HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jonge CT, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge M; PAVord ID, Sears MR, Sterk PJ, Stolfow SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respi-ratory Society Task Force on Asthma Control and Exacerba-tions. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.

20. Research in Real Life: Standard Operating Procedures [Internet]. [cited 2011 Dec 17]. Available from: http://www.optimumpatientcare. org/Docs/SOP%20Observational%20Database%20Studies.pdf.

21. Dekhuijzen PN, Magnan A, Kneussl M; ADMIT Working Group. The ADMIT series - issues in inhalation therapy. 1) The goals of asthma treatment: can they be achieved? Prim Care Respir J 2007;16:341-8.

22. Papa A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011;37:982-5.

23. Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenbein J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009;9:1.

24. Kozyczynski AL, Dahl ME, Ungar WJ, Becker AB, Law BJ. Antibiotic treatment of wheezing in children with asthma: what is the prac-tice? Pediatrics 2006;117:e1104-10.

25. Vanderweil SG, Tsai CL, Pelletier AJ, Espinola JA, Sullivan AF, Blu-menhal D, Camargo CA Jr. Inappropriate use of antibiotics for acute asthma in United States emergency departments. Acad Emerg Med 2008;15:736-43.

26. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovas-cular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338:b81.